Pain Licensing: Upfront Gains Fall As Deals Get More Experimental
Executive Summary
229 alliance deals were signed in the pain management sector between 2012 and November 2016, worth more than $1bn in upfront payments and around $11bn in total potential value. But an increase in deals for riskier, earlier stage assets has pushed down upfront payment values for the sector, knocking it out of sync with other therapy areas.
You may also be interested in...
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.